Fisher & Paykel Healthcare Zukünftiges Wachstum
Future Kriterienprüfungen 5/6
Fisher & Paykel Healthcare wird ein jährliches Gewinn- und Umsatzwachstum von 24.9% bzw. 10.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 24.2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 23.9% betragen.
Wichtige Informationen
24.9%
Wachstumsrate der Gewinne
24.2%
EPS-Wachstumsrate
| Medical Equipment Gewinnwachstum | 19.8% |
| Wachstumsrate der Einnahmen | 10.8% |
| Zukünftige Eigenkapitalrendite | 23.9% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 25 Nov 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
The Returns On Capital At Fisher & Paykel Healthcare (NZSE:FPH) Don't Inspire Confidence
Oct 28
Fisher & Paykel Healthcare Corporation Limited's (NZSE:FPH) Shares May Have Run Too Fast Too Soon
Oct 08Here's Why Fisher & Paykel Healthcare Corporation Limited's (NZSE:FPH) CEO Compensation Is The Least Of Shareholders Concerns
Aug 21Is Fisher & Paykel Healthcare (NZSE:FPH) A Risky Investment?
Jul 29Fisher & Paykel Healthcare (NZSE:FPH) Will Want To Turn Around Its Return Trends
Jul 11Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH) Investors Are Less Pessimistic Than Expected
Jun 22There May Be Reason For Hope In Fisher & Paykel Healthcare's (NZSE:FPH) Disappointing Earnings
Jun 05Is Fisher & Paykel Healthcare (NZSE:FPH) Using Too Much Debt?
Mar 27Be Wary Of Fisher & Paykel Healthcare (NZSE:FPH) And Its Returns On Capital
Feb 22Fisher & Paykel Healthcare Corporation Limited's (NZSE:FPH) Business Is Yet to Catch Up With Its Share Price
Feb 05Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH) Shares Could Be 31% Above Their Intrinsic Value Estimate
Jan 03We Think Fisher & Paykel Healthcare (NZSE:FPH) Can Stay On Top Of Its Debt
Nov 30Fisher & Paykel Healthcare (NZSE:FPH) Could Be Struggling To Allocate Capital
Nov 12Estimating The Fair Value Of Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH)
Aug 28Be Wary Of Fisher & Paykel Healthcare (NZSE:FPH) And Its Returns On Capital
Aug 10Here's Why Fisher & Paykel Healthcare (NZSE:FPH) Can Manage Its Debt Responsibly
Jul 02Be Wary Of Fisher & Paykel Healthcare (NZSE:FPH) And Its Returns On Capital
May 01Returns On Capital Signal Tricky Times Ahead For Fisher & Paykel Healthcare (NZSE:FPH)
Jan 23Does Fisher & Paykel Healthcare (NZSE:FPH) Have A Healthy Balance Sheet?
Dec 27Calculating The Fair Value Of Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH)
Oct 28Shareholders Are Optimistic That Fisher & Paykel Healthcare (NZSE:FPH) Will Multiply In Value
Oct 13Fisher & Paykel Healthcare (NZSE:FPH) Has A Pretty Healthy Balance Sheet
Sep 28Calculating The Fair Value Of Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH)
Jul 24A Look Into Fisher & Paykel Healthcare's (NZSE:FPH) Impressive Returns On Capital
Jul 10Fisher & Paykel Healthcare (NZSE:FPH) Seems To Use Debt Quite Sensibly
Jun 12A Look At The Fair Value Of Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH)
Apr 17Fisher & Paykel Healthcare (NZSE:FPH) Could Become A Multi-Bagger
Apr 04Does Fisher & Paykel Healthcare (NZSE:FPH) Have A Healthy Balance Sheet?
Mar 06With EPS Growth And More, Fisher & Paykel Healthcare (NZSE:FPH) Is Interesting
Jan 22Why The 41% Return On Capital At Fisher & Paykel Healthcare (NZSE:FPH) Should Have Your Attention
Dec 26Is Fisher & Paykel Healthcare (NZSE:FPH) A Risky Investment?
Dec 05This Is The Reason Why We Think Fisher & Paykel Healthcare Corporation Limited's (NZSE:FPH) CEO Deserves A Bump Up To Their Compensation
Aug 11Is Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH) Worth NZ$31.6 Based On Its Intrinsic Value?
Aug 01Do Fisher & Paykel Healthcare's (NZSE:FPH) Earnings Warrant Your Attention?
Jul 07Is Fisher & Paykel Healthcare (NZSE:FPH) A Risky Investment?
Jun 24Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 3/31/2027 | 2,497 | 519 | 385 | 618 | 14 |
| 3/31/2026 | 2,232 | 435 | 293 | 542 | 15 |
| 3/31/2025 | 1,987 | 359 | 314 | 471 | 15 |
| 3/31/2024 | 1,743 | 133 | 91 | 430 | N/A |
| 12/31/2023 | 1,719 | 197 | 61 | 411 | N/A |
| 9/30/2023 | 1,694 | 262 | 31 | 393 | N/A |
| 6/30/2023 | 1,638 | 256 | 29 | 316 | N/A |
| 3/31/2023 | 1,581 | 250 | 27 | 238 | N/A |
| 12/31/2022 | 1,527 | 251 | 6 | 218 | N/A |
| 9/30/2022 | 1,472 | 251 | -15 | 199 | N/A |
| 6/30/2022 | 1,577 | 314 | 70 | 262 | N/A |
| 3/31/2022 | 1,682 | 377 | 155 | 324 | N/A |
| 12/31/2021 | 1,821 | 449 | 259 | 430 | N/A |
| 9/30/2021 | 1,961 | 521 | 363 | 535 | N/A |
| 6/30/2021 | 1,966 | 522 | 402 | 580 | N/A |
| 3/31/2021 | 1,971 | 524 | 441 | 625 | N/A |
| 12/31/2020 | 1,787 | 458 | 344 | 526 | N/A |
| 9/30/2020 | 1,603 | 392 | 247 | 426 | N/A |
| 6/30/2020 | 1,433 | 339 | 199 | 374 | N/A |
| 3/31/2020 | 1,264 | 287 | 151 | 321 | N/A |
| 12/31/2019 | 1,197 | 260 | 133 | 297 | N/A |
| 9/30/2019 | 1,130 | 233 | 115 | 273 | N/A |
| 6/30/2019 | 1,100 | 221 | 117 | 263 | N/A |
| 3/31/2019 | 1,070 | 209 | 120 | 253 | N/A |
| 12/31/2018 | 1,052 | 208 | 135 | 256 | N/A |
| 9/30/2018 | 1,034 | 206 | 151 | 259 | N/A |
| 6/30/2018 | 1,007 | 198 | 150 | 253 | N/A |
| 3/31/2018 | 981 | 190 | 149 | 248 | N/A |
| 12/31/2017 | 954 | 181 | N/A | 224 | N/A |
| 9/30/2017 | 928 | 172 | N/A | 200 | N/A |
| 6/30/2017 | 911 | 171 | N/A | 197 | N/A |
| 3/31/2017 | 894 | 169 | N/A | 194 | N/A |
| 12/31/2016 | 877 | 164 | N/A | 190 | N/A |
| 9/30/2016 | 860 | 160 | N/A | 186 | N/A |
| 6/30/2016 | 838 | 152 | N/A | 165 | N/A |
| 3/31/2016 | 815 | 143 | N/A | 145 | N/A |
| 12/31/2015 | 776 | 135 | N/A | 135 | N/A |
| 9/30/2015 | 736 | 126 | N/A | 126 | N/A |
| 6/30/2015 | 704 | 120 | N/A | 136 | N/A |
| 3/31/2015 | 672 | 113 | N/A | 147 | N/A |
| 12/31/2014 | 655 | 107 | N/A | 134 | N/A |
| 9/30/2014 | 637 | 101 | N/A | 122 | N/A |
| 6/30/2014 | 630 | 99 | N/A | 111 | N/A |
| 3/31/2014 | 623 | 97 | N/A | 100 | N/A |
| 12/31/2013 | 608 | 93 | N/A | 94 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: FPHDas prognostizierte Gewinnwachstum (24.9% pro Jahr) liegt über der Sparquote (3%).
Ertrag vs. Markt: FPHDie Erträge des Unternehmens (24.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt NZ (24.7% pro Jahr).
Hohe Wachstumserträge: FPHEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: FPHDie Einnahmen des Unternehmens (10.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt NZ (4.3% pro Jahr).
Hohe Wachstumseinnahmen: FPHDie Einnahmen des Unternehmens (10.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: FPHDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (23.9%)